Next-generation sequencing for DLBCL patients with early failure after frontline R-CHOP chemo-immunotherapy
{{output}}
Background: Early failure less than 12 months (POD12) of frontline R-CHOP chemo-immunotherapy in very poor outcomes and requires alternative therapy in patients with Diffuse large B-cell lymphoma (DLBCL). ... ...
